Biovail receives approval for Aplenzin for depression

News
Article

Aplenzin is a new drug from Biovail Corp. that has been approved to treat depression in adults

Aplenzin (bupropion hydrobromide), formerly known as BVF-033, is an antidepressant from Biovail Corp. that has just received approval from the Food & Drug Administration. The

Recent Videos
fake news misinformation | Image Credit: Bits and Splits - stock.adobe.com
Related Content
FDA Approves Abuse-Deterrent 10 mg Oxycodone Hydrochloride for Severe Pain

FDA Approves Abuse-Deterrent 10 mg Oxycodone Hydrochloride for Severe Pain

Lauren Massaro
October 29th 2024
Article

The addition of a 10 mg oxycodone hydrochloride tablet improves dosing flexibility and precision.

Looking to the Future of Independent Pharmacy

Looking to the Future of Independent Pharmacy

Miranda Hester
July 13th 2022
Podcast

Don Arthur, RPh, discusses what lays ahead in independent pharmacy, from clinical care to success stories.

FDA Approves Abrysvo for Adults 18-59 at Increased Risk for RSV

FDA Approves Abrysvo for Adults 18-59 at Increased Risk for RSV

Lauren Biscaldi, MS, Managing Editor
October 23rd 2024
Article

Abrysvo is the only RSV vaccine approved for use in this age group.

Podcast: Pharmacy Financing With First Financial Bank

Podcast: Pharmacy Financing With First Financial Bank

January 28th 2022
Podcast

Learn more about the ins and outs of pharmacy ownership from the experts at First Financial Bank.

FDA Approves Ensifentrine, Novel Treatment for Chronic Obstructive Pulmonary Disease

FDA Approves Ensifentrine, Novel Treatment for Chronic Obstructive Pulmonary Disease

Kevin W. Chamberlin, PharmD, FASCP;Molly Csere, PharmD
October 15th 2024
Article

On June 26, 2024, the FDA approved ensifentrine (Ohtuvayre) for the treatment of COPD.

FDA Approves Ceftobiprole Medocaril Sodium for 3 Indications

FDA Approves Ceftobiprole Medocaril Sodium for 3 Indications

Jenny Zhao, PharmD;Kevin W. Chamberlin, PharmD, FASCP
October 14th 2024
Article

The FDA approved ceftobiprole medocaril sodium for injection (Zevtera) in April 2024.

© 2024 MJH Life Sciences

All rights reserved.